好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Demyelination, Inflammation and Axonal Loss Explain Different Patterns of Fractional Anisotropy Abnormalities in MS Cortical Normal Appearing Gray Matter and Lesions
Multiple Sclerosis
P5 - Poster Session 5 (5:30 PM-6:30 PM)
15-024

To define the histopathological substrates of diffusivity abnormalities in cortical normal-appearing gray matter (cNAGM) and cortical lesions (CLs) of patients with multiple sclerosis (PwMS) by combining postmortem diffusion tensor (DT) MRI and histopathology.

In PwMS, a higher fractional anisotropy (FA) has been found in CLs vs cNAGM and is clinically relevant. However, its pathological substrates have yet to be elucidated.

Brain 3DT1 and DT postmortem in situ 3T MRI were obtained from 16 PwMS and 10 non-neurological controls (nNC). At subsequent autopsy,  110 tissue blocks (54 from PwMS, 56 from nNC) were dissected from 6 standardized cortical regions. Tissue regions were matched to 3DT1 and co-registered to DT sequence to obtain regional FA. Cortical density of myelin and microglia, axon number and orientation, number and size of neurons and glial cells were evaluated. Histopathological correlates of diffusivity alterations were assessed through linear mixed models for nested data.

CLs (subpial=77%) were found in 27/54 cortical regions from PwMS. cNAGM of PwMS had a significantly lower FA vs nNC (p=0.04), whereas in PwMS CLs vs cNAGM had a higher FA (p=0.003). Compared to nNC, cNAGM in PwMS showed a lower density of perpendicular and total axons (p≤0.02). In PwMS, CLs vs cNAGM had a lower density of myelin, parallel and total axons (p≤0.02). Regarding the pathological substrate, nNC cNAGM FA was positively associated with density of perpendicular, parallel and total axons (p≤0.005). In PwMS, cNAGM FA was positively associated with density of myelin, glial and total cells and perpendicular, parallel and total axons (p≤0.05), while CLs FA was positively associated with neuron and total cell density and negatively with microglia density (p≤0.05).

Demyelination, inflammation and variable loss of axons with different orientations, determine cortical microstructural abnormalities contributing to explain the different patterns of FA changes occurring in cNAGM and CLs of PwMS.

Authors/Disclosures
Paolo Preziosa (Ospedale San Raffaele)
PRESENTER
Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
No disclosure on file
No disclosure on file
Alessandro Meani Alessandro Meani has nothing to disclose.
No disclosure on file
No disclosure on file
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
No disclosure on file
No disclosure on file